Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21322827 | 1.00 | MEN1 (0.45) | MEN1KMT2ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL15277928 | 0.90 | MAPT (0.53) | MEN1KMT2ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL20117644 | 0.89 | LMNA (0.42) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15849107 | 0.88 | MAPT (0.44) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1110657 | 0.86 | SRPK1 (0.55) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL1110656 | 0.86 | SRPK1 (0.55) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL1110655 | 0.86 | SRPK1 (0.55) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL15277956 | 0.82 | KDR (0.44) | MEN1KMT2ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL15277931 | 0.80 | SRPK1 (0.44) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15277927 | 0.79 | KDR (0.55) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188382-A1 | PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS | KYOTO UNIVERSITY (JP) | 2020-06-18 | — | — | US | disclosed |
| WO-2018079855-A1 | PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS | 国立大学法人京都大学 | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188382-A1 | PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS | CASP3, BAX, BAD | MEN1 2821/4885KMT2A 4487/4885LMNA 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.